| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027 |
| 02 Oct 2026 |
8-K: Other Events
BioAge Labs, Inc. (the “Company”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular e... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026 |
| 01 Jul 2026 |
Form 4: Barton Shane, Principal Accounting Officer
Received 39,718 shares by exercise or conversion ($263K) · Sold 42,350 shares ($1.07M) · Received 20,216 shares by exercise or conversion ($132K) · 1 more |
| 30 Jun 2026 | 144 |
| 29 Jun 2026 | 144 |
| 12 Jun 2026 |
Form 4: Hemrajani Rekha, Director
Granted 22,000 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Enright Patrick G, Director
Granted 22,000 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Pande Vijay Satyanand, Director
Granted 22,000 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Healy James, Director
Granted 22,000 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Davidson Michael H., Director
Granted 22,000 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Garnier Jean Pierre, Director
Granted 22,000 Stock Option (Right to Buy) |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2026, BioAge Labs, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders and the Company’s stockholders voted on and approved the following proposals: |
| 15 May 2026 | SCHEDULE 13G/A |
| 15 May 2026 | SCHEDULE 13G/A |
| 08 May 2026 |
8-K: Results of Operations and Financial Condition
Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk |
Loading...